The Management Board of Selvita S.A. with its registered office in Krakow (“Issuer”) hereby informs that on December 15, 2022 the Issuer’s subsidiary – Selvita Inc. received from a biotechnology company based in the United States (the “Client”) a work order under a framework agreement concluded with the Client on August 22, 2016, the subject of which is to provide support for the Client’s drug discovery platform in the field of medicinal chemistry, involving synthesis of chemical compounds indicated by the Client (“Work Order”).

The value of the Work Order, which is to be executed over the following 6 months, amounts to USD 1,297,224 (PLN 5,720,757.84 converted at the average exchange rate of the National Bank of Poland USD 1 = PLN 4.4100 of December 15, 2022). The Work Order will involve medicinal chemistry support in the FTE model such as a synthesis of compounds for biological evaluation and a synthesis of intermediates for Client’s internal needs.

The Issuer’s cooperation with the Client has been ongoing since 2016, and the Issuer informed about the previous extension of cooperation with the Client in current report no. 4/2020 dated February 19, 2020 and in current report no. 2/2022 dated January 10, 2022. Considering the value of the purchase order, as well as the fact of an extension of significant cooperation with the Client, the Management Board of the Issuer considers the Purchase Order to be significant.

Legal basis:
Art. 17.1 of MAR

Representatives of the Company:     

  • Bogusław Sieczkowski – President of the Management Board
  • Miłosz Gruca – Vicepresident of the Management Board